CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
  • Home
    • About
      • Message from the Editor-in-Chief
      • Mission Statement
      • Editorial Board
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
Search
  • Home
    • About
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
Follow US
AHA 2026News

Increasing Atrial Fibrillation Density is Associated with Heart Failure Onset and Hospitalizations

Leah Kosyakovsky
Share
5 Min Read

Key Points:

  • While atrial fibrillation (AF) is a known, prominent risk factor for heart failure (HF) with both preserved (HFpEF) and reduced ejection fraction (HFrEF), it is currently unclear whether increasing AF density is associated with a commensurate increase in HF risk.
  • In this nationwide cohort study, increasing AF density demonstrated a dose-response relationship with both new HF onset and HF hospitalizations, with consistent associations observed across all ejection fraction strata.

While the presence of atrial fibrillation (AF) is a critical risk factor for heart failure (HF), attempts to stratify HF risk by traditional features of AF (i.e., burden, duration of longest episode) have yielded poor results. More recently, the concept of AF density—which, as opposed to total burden of AF, represents the temporal distribution of AF episodes during a given monitoring period, and which has recently been identified as a novel biomarker for ischemic stroke risk—has emerged as an alternate approach to stratifying HF risk. In a presentation at the American Heart Association Scientific Sessions on November 7, 2026, Dr. Lindsey Rosman and her team presented their study: “Rethinking atrial fibrillation burden: AF density further stratifies heart failure risk in a nationwide cohort of patients with cardiac devices.”

A total of 86,233 patients with implantable cardiac devices across both the Veterans Health Administration and the University of North Carolina (UNC) Health System were identified. Relevant exclusions were lack of AF monitoring data, accelerometers, >10% missing AF data, the presence of an LVAD or heart transplant, permanent AF, and device-detected AF under six minutes during follow-up. Ultimately, 15,877 Veterans Health patients (mean age 73.1 years, 45% with baseline HF, median EF 52% at implant) and 3,525 UNC patients (mean age 73.5 years, 46% with baseline HF, median EF 55%) were analyzed. 

The primary analysis examined the association between AF density and the adjusted one-year risk of new-onset HF, among those patients without HF at time of implant. Secondary analyses also examined the association of AF density with adjusted one-year risk of HF hospitalization, among those with baseline HF, as well as examining the joint effects of both AF density and burden on both outcomes. AF density was treated as a categorical variable (with groups of low, medium, medium-high, and high density).

Increasing AF density was associated with increased risk of new-onset HF, with a 24% increased adjusted hazard observed in medium density AF (RR 1.24, 95% CI 1.20-1.29), a 50% increased adjusted risk observed in medium-high density AF (RR 1.50, 95% CI 1.41-1.61), and a 72% increased adjusted risk observed in high density AF (RR1.72, 95% CI 1.57-1.88), all relative to the low-density referent group. Similar effects were seen across all clinically relevant subgroups, including those with and without baseline AF, men and women, older (age >65 years) and younger adults, and those with ischemic cardiomyopathy. Increasing AF density was similarly associated with increased HF hospitalization among those with preexisting HF, with more than doubling of the adjusted hazard among those with high AF density (RR 2.06, 95% CI 1.95-2.18). Findings were consistent across all forms of baseline HF (including those with reduced, mildly reduced, and preserved ejection fraction) as well as all prior clinical subgroups. Increased AF density also further increased the risk of HF associated with AF burden; those with both high AF burden and density carried approximately three times the adjusted risk of both new HF (RR 3.47, 95% CI 3.21-3.75) and HF hospitalization (HR 2.65, 95% CI 2.51-2.79).

When discussing the strengths and weaknesses of the study at the Scientific Sessions, Dr. Rosman stated: “strengths included continuous device-detected data from multiple manufacturers and two large health systems…limitations included possible EHR misclassification, lack of NYHA class in symptom data, and variability in AF detection by device.”

TAGGED:AHA 2026ConferenceFeaturedNews
Share This Article
Copy Link Print
CardiologyNowNews.org CardiologyNowNews.org
Copyright - CardiologyNowNews
  • Contact Us
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?